ReviewMolecules (Basel, Switzerland)2017
New Insights in the Design of Bioactive Peptides and Chelating Agents for Imaging and Therapy in Oncology.
Review in Molecules (Basel, Switzerland), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 77 citations in OpenAlex.
- From Innate Immunity to Cancer Therapy: Antimicrobial Peptides as Emerging Anticancer Agents.International journal of molecular sciences · 2026Review
- Peptide Drugs in Gastrointestinal Tumors: Integrating Targeting, Delivery, and Therapeutic Actions for Synergistic Strategies.Biomolecules · 2026Review
- Two-dimensional graphene nanomaterials for combined photothermal and chemotherapy-enhanced targeted therapy of breast cancer.Materials today. Bio · 2025Article
- Synthesis, Radiolabeling, and Biodistribution Study of a Novel DOTA-Peptide for Targeting Vascular Endothelial Growth Factor Receptors in the Molecular Imaging of Breast Cancer.Pharmaceutics · 2024Article
- The State-of-the-Art Mechanisms and Antitumor Effects of Somatostatin in Colorectal Cancer: A Review.Biomedicines · 2024Review
- Stabilizing Scaffold for Short Peptides Based on Knottins.Current cancer drug targets · 2024Article
- Development and Synthesis of Bombesin-Based Radiopharmaceutical Precursors Modified with Knottin.Sovremennye tekhnologii v meditsine · 2024Article
- Clinical Advances and Perspectives in Targeted Radionuclide Therapy.Pharmaceutics · 2023Review
- Targeting Peptides: The New Generation of Targeted Drug Delivery Systems.Pharmaceutics · 2023Review
- Article
- From Automated Synthesis to In Vivo Application in Multiple Types of Cancer-Clinical Results with [Pharmaceuticals (Basel, Switzerland) · 2022Article
- Hybridization of tumor homing and mitochondria-targeting peptide domains to design novel dual-imaging self-assembled peptide nanoparticles for theranostic applications.Drug delivery and translational research · 2022Article
- Natural product-based radiopharmaceuticals: Focus on curcumin and its analogs, flavonoids, and marine peptides.Journal of pharmaceutical analysis · 2022Review
- Circumsporozoite Protein ofPharmaceutics · 2022Article
- Multifunctional self-assembled peptide nanoparticles for multimodal imaging-guided enhanced theranostic applications against glioblastoma multiforme.Nanoscale advances · 2021Article
- High-resolution positron emission microscopy of patient-derived tumor organoids.Nature communications · 2021Article
- Artificial Intelligence and the Future of Diagnostic and Therapeutic Radiopharmaceutical Development:: In Silico Smart Molecular Design.PET clinics · 2021Review
- Distinctive detection of insulinoma using [Scientific reports · 2021Article
- Molecular Imaging of Angiogenesis in Oncology: Current Preclinical and Clinical Status.International journal of molecular sciences · 2021Review
- Synthesis of Poly(Malic Acid) Derivatives End-Functionalized with Peptides and Preparation of Biocompatible Nanoparticles to Target Hepatoma Cells.Nanomaterials (Basel, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Many synthetic peptides have been developed for diagnosis and therapy of human cancers based on their ability to target specific receptors on cancer cell surface or to penetrate the cell membrane. Chemical modifications of amino acid chains have significantly improved the biological activity, the stability and efficacy of peptide analogues currently employed as anticancer drugs or as molecular imaging tracers. The stability of somatostatin, integrins and bombesin analogues in the human body have been significantly increased by cyclization and/or insertion of non-natural amino acids in the peptide sequences. Moreover, the overall pharmacokinetic properties of such analogues and others (including cholecystokinin, vasoactive intestinal peptide and neurotensin analogues) have been improved by PEGylation and glycosylation. Furthermore, conjugation of those peptide analogues to new linkers and bifunctional chelators (such as AAZTA, TETA, TRAP, NOPO etc.), produced radiolabeled moieties with increased half life and higher binding affinity to the cognate receptors. This review describes the most important and recent chemical modifications introduced in the amino acid sequences as well as linkers and new bifunctional chelators which have significantly improved the specificity and sensitivity of peptides used in oncologic diagnosis and therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.